Efficacy and safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in patients with severe hemophilia A: results from the guardian^TM2 trial

¹Department of Hematology/Oncology, University Children's Hospital, Tirsova 10, Belgrade, Serbia;

²Haemophilia Centre, National Blood Centre, Kuala Lumpur, Malaysia;

³Hemophilia Medical & Science, Novo Nordisk A/S, Søborg, Denmark;

⁴IHTC “Claudio L. P. Correa” INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, Brazil;

⁵Clinic of Hematology, Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 1-3, Novi Sad, Serbia;

⁶Hannover Medical School, Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; and

⁷University Clinic Bonn AöR, Institute of Experimental Haematology and Transfusion Medicine Sigmund-Freud-Str. 25 53127 Bonn Germany, Bonn, Germany